A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Encephalopathy of prematurity encompasses the central nervous system abnormalities associated with injury from preterm birth. This report describes a clinically relevant rat model of in utero transient systemic hypoxia-ischemia and intra-amniotic lipopolysaccharide administration (LPS) that mimics chorioamnionitis, and the related impact of infectious stimuli and placental underperfusion on CNS development.
Encephalopathy of prematurity (EoP) is a term that encompasses the central nervous system (CNS) abnormalities associated with preterm birth. To best advance translational objectives and uncover new therapeutic strategies for brain injury associated with preterm birth, preclinical models of EoP must include similar mechanisms of prenatal global injury observed in humans and involve multiple components of the maternal-placental-fetal system. Ideally, models should produce a similar spectrum of functional deficits in the mature animal and recapitulate multiple aspects of the pathophysiology. To mimic human systemic placental perfusion defects, placental underperfusion and/or chorioamnionitis associated with pathogen-induced inflammation in early preterm birth, we developed a model of prenatal transient systemic hypoxia-ischemia (TSHI) combined with intra-amniotic lipopolysaccharide (LPS). In pregnant Sprague Dawley rats, TSHI via uterine artery occlusion on embryonic day 18 (E18) induces a graded placental underperfusion defect associated with increasing CNS damage in the fetus. When combined with intra-amniotic LPS injections, placental inflammation is increased and CNS damage is compounded with associated white matter, gait and imaging abnormalities. Prenatal TSHI and TSHI+LPS prenatal insults meet several of the criteria of an EoP model including recapitulating the intrauterine insult, causing loss of neurons, oligodendrocytes and axons, loss of subplate, and functional deficits in adult animals that mimic those observed in children born extremely preterm. Moreover, this model allows for the dissection of inflammation induced by divergent injury types.
With over 12% of infants born in the United States before 37 weeks estimated gestational age1, perinatal brain injury (PBI) from prematurity is a significant cause of permanent disability. PBI from prematurity, also termed encephalopathy of prematurity (EoP), affects the entire central nervous system (CNS). CNS injury often commences in utero, and is exacerbated by antenatal processes including chorioamnionitis and postnatal complications such as hypoxia and sepsis. PBI from systemic insults alters neurodevelopment and leads to cerebral palsy, epilepsy, cognitive delay and numerous neuropsychiatric disorders affecting emotional regulation, memory and executive function1,2. Although much progress has been made, a limited understanding remains of how the cellular and molecular consequences of CNS injury from preterm birth translate to the multitude of neurological sequelae in children who are born preterm. This lack of knowledge hinders real-time diagnosis of CNS injury severity and informed dosing of emerging interventions. Additionally, age-appropriate therapeutic strategies for this vulnerable patient population remain elusive.
Intrauterine inflammation is very common in extreme prematurity and involves a complex fetal-maternal-placental inflammatory cascade3. Intrauterine infection is often subclinical. Specific placental findings consistent with acute inflammation, or histologic chorioamnionitis, are major determinants of the fetal inflammatory response and are coincident with brain injury associated with preterm birth3-5. Indeed, the fetal inflammatory response has distinct clinical implications for long-term outcomes from preterm birth. Infants who are small for gestational age (SGA) or who experience infection are exceptionally vulnerable to neurological deficits3,4. Chorioamnionitis is a typical pathological diagnosis following preterm birth6,7, and histological examination reveals signs of inflammation in 70% of placentas from infants born very preterm4. Further, chorioamnionitis is associated with cognitive impairment at two years8. Evidence of maternal vascular underperfusion in the placenta of infants born extremely preterm is also associated with cerebral palsy in childhood9. The synergistic impact of chorioamnionitis and placental perfusion defects is well illustrated by the remarkably high risk of abnormal neurologic outcomes in this patient population at two years of age10,11.
To mimic human systemic placental perfusion defects and chorioamnionitis associated with pathogen-induced inflammation, we developed a model of prenatal transient systemic hypoxia-ischemia (TSHI) combined with intra-amniotic lipopolysaccharide (LPS) in rats. Our goal was to adapt our model of TSHI alone in rats12-16 to include intrauterine inflammation, to facilitate preclinical modeling of CNS injury associated with preterm birth. TSHI alone has revealed persistent loss of oligodendroglial lineage cells, cortical neurons, increased cell death, and elevated pro-inflammatory cytokine levels, with progressive ischemic intervals leading to a graded pattern of injury consistent with prenatal brain injury16. Modifications to the ischemic components of this model have also demonstrated deficits in memory encoding, short and long-term memory and mild musculoskeletal alterations in rats as they age17-19. Indeed, we have previously demonstrated that the combination of TSHI+LPS recapitulates the pathophysiological hallmarks of EoP, including oligodendrocyte and neuronal loss, axonal injury, cellular inflammation and functional abnormalities20.
Institutional Care and Use Committees at both Boston Children’s Hospital and the University of New Mexico Health Sciences Center approved all experimental procedures.
NOTE: Prior to commencing the procedure, seal, sterilize and autoclave all surgical instruments and surgical drapes. Additionally, prepare post-operative medications in sterile vials including 0.125% bipivucaine and 0.1 mg/kg buprenorphine. Also prepare the lipopolysaccharide (LPS) solution sterilely: 0.04 mg/ml LPS (0111:B4) in sterile saline containing dilute Evan’s blue dye.
1. Anesthesia
2. Surgical Prep and Scrub
3. Abdominal Laparotomy
4. Placement of Aneurysm Clips
5. Injection of Lipopolysaccharide in to Amniotic Sacs
6. Closing the Laparotomy
7. Postoperative Recovery and Care
8. Tissue Processing and Cryosectioning
9. Hematoxylin & Eosin Staining
Following TSHI+LPS at E18, hematoxylin and eosin staining reveals significant histopathological abnormalities in both the placenta (Figure 1) and in the brain (Figure 2). Placentas examined on E19 and E21 are grossly edematous with micro-hemorrhage, and necrosis throughout the decidua and labyrinth. Significant inflammatory infiltrate and increased vascularity is also observed. Brains examined on P2 reveal ventriculomegaly, as well as white matter and subplate neuron loss compared to sha...
Encephalopathy of prematurity is difficult to model in animals because of the complex interaction of etiologies, neurodevelopmental time course, intricacy of human cerebral network formation, overlapping mechanisms of injury, and the diverse phenotypes of CNS insults manifest in human preterm infants. EoP is associated with specific cell-type vulnerabilities (i.e. immature oligodendrocytes)21, as well as diverse developmentally-regulated pathways (i.e. subplate, membrane transporters and rece...
The authors have nothing to disclose.
The authors are grateful to Dan Firl, Chris Corbett and Jesse Denson, PhD. Funding was provided by NIH NINDS R01 NS060765 to SR, the P30 CoBRE Pilot Program to LJ and the Child Health Signature Program to LJ at the University of New Mexico.
Name | Company | Catalog Number | Comments |
Saline Solution, 0.9% | Sigma | S8776 | |
LPS 011B4 | Sigma | L2630 | |
Evan's Blue Dye | Sigma | E2129 | |
Surgical gloves | Biogel | 40870 | |
OR Towels | Cardinal Health | 287000-008 | Sterile |
PDI Alcohol Prep Pads | Fisherbrand | 06-669-62 | |
Mini Arco Rechargeable Clippers | Kent Scientific Corp. | CL8787 | |
Betadine surgical scrub | Purdue Products L.P. | 67618-151-17 | |
Eye Lubricant | Refresh Lacri Lube | 00023-0312 | |
Blunt Forceps | Roboz | RS-8100 | |
Scissors | Roboz | RS-6808 | |
Surgical Scissors | Roboz | RS-5880 | |
Surgical Scissors | F.S.T. | 14002-16 | |
Syringe | BD | 309628 | 1 ml |
Needle | BD | 305122 | 25G 5/8 |
Needle | BD | 305128 | 30G 1 |
Cotton-tipped Applicators | Fisherbrand | 23-400-114 | Small, 6 inch sterile |
Cotton Gauze Sponge | Fisherbrand | 22-362-178 | |
Needle Holders | Kent Scientific Corp. | INS600109 | 12.5 CM STR |
Vessel Clips | Kent Scientific Corp. | INS600120 | 30G Pressure |
3-0 Perma Hand Silk Sutures | Ethicon | 1684G | Black braided, 3-0 (2 metric), 18", non-absorbable, PS-1 24 mm needle, 3/8 circle |
Insulin Syringes | BD | 328438 | 0.3 cc 3 mm 31G |
Pentobarbital | |||
Buprenorphine | |||
Bupivacaine | |||
Isoflurane | |||
Lithium Carbonate | Acros Chemicals | 554-13-2 | |
Superfrost Plus Microscope Slides | VWR | 48311-703 | |
Hematoxylin | Leica | 3801521 | Surgipath Gill II Hematoxylin |
Eosin | Leica | 3801601 | Surgipath Eosin |
Xylenes | Fisherbrand | X3S-4 | Histological Grade |
Permount | Fisherbrand | SP15-100 | |
Coverglass | Fisherbrand | 12-548-5P | Fisher Finest Premium Coverglass |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved